A 68-year-old woman from Mumbai with Parkinson disease on levodopa–carbidopa for 8 years presents with involuntary writhing movements of her limbs and trunk that occur 2–3 hours after taking her morning dose. She also reports periods of sudden immobility lasting 10–15 minutes, followed by return of normal movement. Her levodopa dose is 500 mg/day in divided doses. What is the most likely explanation for her current motor complications?

Explanation

## Clinical Presentation of Motor Complications This patient exhibits two hallmark **levodopa-induced motor complications**: ### 1. Dyskinesia (Involuntary Movements) - Writhing, choreiform movements of limbs and trunk - Peak-dose dyskinesia: occurs 2–3 hours after dose (at peak levodopa levels) - Develops in ~40% of patients after 4–6 years of levodopa therapy ### 2. Motor Fluctuations ("On-Off" Phenomenon) - **"Off" periods:** sudden immobility (10–15 min) when drug levels drop - **"On" periods:** normal mobility when drug levels are adequate - Reflects loss of striatal dopamine buffering capacity ## Pathophysiology **Key Point:** The striatum normally maintains steady dopamine levels via presynaptic storage and reuptake. In advanced PD, degeneration of dopamine neurons eliminates this buffering. Oral levodopa is absorbed intermittently, creating **pulsatile (on-off) dopaminergic stimulation** rather than continuous tone. **High-Yield:** Pulsatile stimulation → abnormal sensitization of postsynaptic D1/D2 receptors → dyskinesia and motor fluctuations. ## Why This Is Not Disease Progression, Secondary Syndrome, or Overdose | Feature | Levodopa-Induced Complications | Disease Progression | Secondary Syndrome | Overdose | |---------|--------------------------------|-------------------|-------------------|----------| | **Timing relation to dose** | Peak-dose or diphasic | Gradual, independent | Independent | Dose-dependent | | **Reversibility** | Partially (with dose adjustment) | Progressive | Progressive | Reversible | | **Typical onset** | 4–8 years of therapy | Continuous | Variable | Acute | | **Response to dose reduction** | May worsen "off" periods | No improvement | No improvement | Improves | **Clinical Pearl:** The **"levodopa paradox"**: increasing the dose worsens dyskinesia; decreasing it worsens rigidity and bradykinesia. Management requires **continuous dopaminergic stimulation** via: - Extended-release formulations - Dopamine agonist adjuncts - MAO-B inhibitors - COMT inhibitors (entacapone) - Deep brain stimulation (DBS) if severe **Mnemonic — Motor Complications Timeline:** **PULSED** = **P**ulsatile dopamine → **U**nstable receptor response → **L**oss of buffering → **S**triatal degeneration → **E**arly dyskinesia and **D**ysfunction.